Over-expression of OCT4 is found in lung cancer-derived CD133- and CD44-positive cells, anticancer drug-selected breast cancer cells [18–22], which exhibit enhanced resistance to chemotherapeutic agents. Here, PROM1 is linked to breast carcinoma.